STOCK TITAN

Seres Therapeutics' Matthew R. Henn sells 101 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Seres Therapeutics, Inc. President and Chief Scientific Officer Matthew R. Henn reported exercise or conversion of 141 and 97 restricted stock units on November 15, 2026, and acquisition of 238 common shares that day. He sold 101 common shares on November 16 at $1.38 per share. The sale was made under a Rule 10b5-1 instruction adopted April 13, 2023, solely to cover taxes related to restricted-stock-unit vesting.

Insider Henn Matthew R
Role See Remarks
Sold 101 shs ($139.38)
Approx. gross sale proceeds $139.38
Type Security Shares Price Value
Sale Common Stock F2 101 $1.38 $139.38
Exercise Restricted Stock Units F1, F3 141 $0.00 $0.00
Exercise Restricted Stock Units F1, F4 97 $0.00 $0.00
Exercise Common Stock F1 238 -- --
Holdings After Transaction: Restricted Stock Units — 629 units (Direct); Common Stock — 8,132 shares (Direct)
Footnotes (4)
  1. F1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
  3. F3. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
  4. F4. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Common shares sold 101 shares November 16, 2026; Matthew R. Henn
Sale price $1.38 per share Common-stock sale on November 16, 2026
Restricted stock units exercised or converted 141 units November 15, 2026
Restricted stock units exercised or converted 97 units November 15, 2026
Common shares acquired 238 shares November 15, 2026
Rule 10b5-1 instruction regulatory
"pursuant to a Rule 10b5-1 instruction"
restricted stock unit financial
"Each restricted stock unit represents a contingent right"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MCRB shares did Matthew R. Henn sell, and at what price?

Matthew R. Henn sold 101 Seres Therapeutics common shares on November 16, 2026, at $1.38 per share. The sale was made under a Rule 10b5-1 instruction adopted April 13, 2023, solely to cover taxes in connection with restricted-stock-unit vesting.

What RSU activity did Matthew R. Henn report for MCRB?

On November 15, 2026, he reported exercise or conversion of 141 and 97 restricted stock units and acquisition of 238 common shares. Each restricted stock unit represents a contingent right to receive one share of Seres Therapeutics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Henn Matthew R

(Last)(First)(Middle)
C/O SERES THERAPEUTICS, INC.
101 CAMBRIDGE PARK DRIVE

(Street)
CAMBRIDGE MASSACHUSETTS 02140

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/15/2026M238A(1)8,233D
Common Stock11/16/2026S(2)101D$1.388,132D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)11/15/2026M141 (3) (3)Common Stock141$0141D
Restricted Stock Units(1)11/15/2026M97 (4) (4)Common Stock97$0488D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
3. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
4. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Remarks:
President and Chief Scientific Officer
/s/ Thomas J. DesRosier, Attorney-in-Fact for Matthew R. Henn11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading